Connect with us

Technology

Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals

Published

on

Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment

BOSTON, March 5, 2025 /PRNewswire/ — Linus Health has announced that it has hit a major milestone with over 145 peer-reviewed studies conducted and authored by leaders and staff from the company and its affiliates. Since 2019, Linus Health and its affiliates have published 72 peer-reviewed publications and delivered 75 scientific presentations at academic conferences. Linus Health is revolutionizing brain health with trusted, science-driven solutions, delivering a comprehensive, end-to-end strategy that supports early detection, intervention, and continuous care across all settings.

The majority of the published research features investigations and validations of the efficacy and accuracy of various elements and solutions within the Linus Health platform designed to promote brain health, detect early indicators of cognitive impairment, and predict the risk of Alzheimer’s disease and other forms of dementia.

To date, Linus Health has completed more than 40 clinical trials and 25 validation studies and has filed 33 patents supporting its technology, which is available in 18 languages.

“These landmark achievements reflect Linus Health’s unwavering dedication to scientific validation as we scale and enhance our offerings and capabilities,” said Linus Health Co-Founder and Chief Medical Officer Alvaro Pascual-Leone, MD, PhD. “This is a bench to bedside commitment, ensuring that we are at the forefront of advancing brain health within both life sciences and healthcare.”

A sampling of some of the most noteworthy recent studies published by Linus Health clinicians and researchers includes:

The Journal of Alzheimer’s Disease, November 2024: Detecting functional impairment with the Digital Clock and Recall. Linus Health Digital Clock and Recall (DCR™) assessment delivers a clinically meaningful evaluation of functional impairment and accurately identifies which patients require more comprehensive care, such as advanced diagnostic testing, specialist referrals, and care partner support.

Scientific Reports, September 2024: Digital speech hearing screening using a quick novel mobile hearing impairment assessment: an observational correlation study. The authors concluded that Linus Health’s digital hearing screening tool quickly, efficiently, and accurately identifies early signs of speech hearing impairment compared to lengthier audiometric tests.

Frontiers in Neurology, June  2024: Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes. The article describes a technology-enabled, scalable approach to guide clinical decisions and outcome evaluations about brain health that effectively incorporate patients’ treatment priorities.

Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring, February 2024: Clinical classification of memory and cognitive impairment with multimodal digital biomarkers. The article demonstrates the great utility of multimodal assessment with the DCR for identifying verbal memory impairment as confirmed by the Rey Auditory Verbal Learning Test (RAVLT).

Alzheimer’s Research & Therapy, January 2024: Digital Clock and Recall is superior to the Mini‑Mental State Examination for the detection of mild cognitive impairment and mild dementia. Results of a clinical trial show that the DCR outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and mild dementia and with less ethnic bias.

Research Strength Matches Company Growth
Meanwhile, Linus Health continues to expand and diversify the company while raising awareness of its capabilities through awards and high-profile speaking engagements.

Acquisitions. Since 2020, Linus Health has completed four acquisitions. Most recently, it acquired Aural Analytics, a leader in clinical-grade speech analytics, and Together Senior Health, a brain health company delivering evidence-based solutions for individuals with cognitive decline due to Alzheimer’s disease and related dementias. In 2022, it acquired Kinesis Health Technologies, a leader in physical function assessment for older adults; and in 2020, it acquired Digital Cognition Technologies, a leader in digital cognitive assessment.

Awards. Linus Health has earned numerous prestigious digital health and technology awards over the years. Most recently, Linus Health was named one of Fierce Healthcare’s Fierce 15 of 2025, an annual special report highlighting innovative and creative private healthcare companies striving to change the world by changing the healthcare industry. Linus Health was also named the “Best in Class” winner in the Digital Health Hub Foundation’s Digital Health Awards 2024 in the Longevity category. The awards recognize companies that “hold the promise of transforming healthcare systems by improving access, efficiency, quality of care, patient outcomes, and addressing cost challenges,” according to its founders.

Speaking Engagements. John Showalter, MD, MSIS, chief strategy officer of Linus Health, was invited to discuss breakthroughs in the early detection of dementia at the HLTH Event 2024 in Las Vegas. Participating in the “Brainiacs” panel, Showalter explained how primary care physicians and neurologists can leverage innovative digital tools that can make early detection of mild cognitive impairment, the precursor of dementia, as routine as any other preventive screening.

In 2024, Ali Jannati, MD, PhD, director of cognitive science at Linus Health, presented the company’s latest research on concurrent identification of cognitive impairment and likely amyloid-beta status on PET using the DCR in a featured research panel at the Alzheimer’s Association International Conference (AAIC) in Philadelphia. Stina Saunders, PhD, personalized medicine lead at Linus Health, delivered an AAIC presentation focusing on the company’s electronic person-specific outcome measure tool. In addition, Linus Health scientists delivered 10 poster presentations at AAIC. More than 14,000 attendees joined the world’s largest dementia conference for its robust scientific program.

Linus Health leaders were also invited to deliver 4 unique poster presentations at the 17th annual Clinical Trials on Alzheimer’s Disease conference in Madrid, Spain. The global conference attracts over 2,000 leading experts onsite and online to discuss the latest therapeutic advances in Alzheimer’s disease.

“Our many achievements and growing industry recognition reflect an emerging consensus that the best clinical pathway to help more people prevent the progression of dementia and other forms of cognitive impairment is through promotion of brain health, prevention of disease, early detection, and evidence-based lifestyle modifications,” said Linus Health Co-Founder and CEO David Bates, PhD. “Our learnings, as well as those of our peers, will continue to inform our solution development in the coming years as we look forward to helping more patients achieve optimal outcomes and a higher quality of life.”

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow us on LinkedIn.

Media Contact
Tara Stultz (Amendola for Linus Health)
440-225-9595
tstultz@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/linus-health-achieves-landmark-research-recognition-across-peer-reviewed-medical-and-scientific-journals-302393368.html

SOURCE Linus Health

Continue Reading

Technology

Cboe Clear U.S. Receives SEC Approval to Expand Clearing Capabilities

Published

on

By

SEC registration enables Cboe Clear U.S. to clear binary securities options alongside futures, positioning it to support innovation across the market

CHICAGO, Oct. 23, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced that Cboe Clear U.S., LLC (CCUS) has received temporary registration from the U.S. Securities and Exchange Commission (SEC) to operate as a Covered Clearing Agency.

The registration expands CCUS’s clearing capabilities beyond its existing authorities as a Commodity Futures Trading Commission (CFTC)-registered Derivatives Clearing Organization (DCO) to clear securities products in addition to futures and swaps products. Together with recent enhancements to its regulatory framework and product scope, the milestone positions CCUS to support innovation and emerging opportunities across a broad range of assets and markets.

CCUS will initially use its SEC registration to clear Cboe’s binary securities options tied to specified corporate key performance indicators (KPIs), which are planned to list on Cboe Options Exchange and be available on Robinhood in the fourth-quarter 2026. CCUS also recently received CFTC approval to clear margined futures broadly and continues to clear digital asset derivatives under its DCO designation.

“Clearing plays a critical role in bringing innovation to market,” said Dale Michaels, Head of Cboe Clear U.S. “These expanded capabilities position Cboe Clear U.S. to become an innovation lane to support new products and meet evolving customer needs, while maintaining the rigorous risk management standards that are fundamental to our business.”

These efforts complement Cboe’s longstanding partnership with The Options Clearing Corporation (OCC)® and Cboe’s continued commitment to supporting the established clearing infrastructure for traditional equity options.

The development builds on the growth of Cboe’s established European clearing business, where Cboe Clear Europe has become the leading pan-European equities central counterparty, while expanding into new services such as securities financing transaction clearing. Together, these advances demonstrate Cboe’s ability to extend its clearing capabilities across markets and asset classes.

To support its own future growth, CCUS has strengthened its infrastructure over the past year, including electing in June to become a Subpart C DCO. In doing so, CCUS is voluntarily adopting the enhanced standards the CFTC applies to systemically important DCOs for financial resources, risk management and operational resilience, aligning with those applied to leading global clearing organizations.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world’s first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world’s leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

Cboe Media Contacts

 

Cboe Analyst Contact

 

Angela Tu

+1-646-856-8734

atu@cboe.com

Tim Cave

+44 (0) 7593-506-719

tcave@cboe.com

Kenneth Hill, CFA

+1-312-786-7559

khill@cboe.com

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor’s Financial Services LLC. All other trademarks and service marks are the property of their respective owners. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our  clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cboe-clear-us-receives-sec-approval-to-expand-clearing-capabilities-302918297.html

SOURCE Cboe Global Markets, Inc.

Continue Reading

Technology

Hears Everything, Uploads Nothing: VoxNexus Launches Android’s First Low-Power On-Device Always-On Voice Artificial Intelligence (AI)

Published

on

By

VoxNexus’ new on-device ambient listening solution runs for 12 hours on 2.49% of a phone’s battery and never sends audio to the cloud

MADRID, Oct. 23, 2026 /PRNewswire/ — VoxNexus (www.VoxNexus.ai) released VoxEdge, an on-device voice stack that brings speech recognition, translation and speech synthesis to affordable Android devices, entirely offline. VoxEdge supports speech recognition in 36 languages, translation in 103 languages, and speech synthesis in 45 languages—all running with no connection, no data bundle, and no cloud token bills.

AI should work for everyone, not just for speakers of a handful of mainstream languages. Yet across much of Africa, voice AI has been held back by scarce training data and the lack of targeted fine-tuning. Everyday speech also includes code-switching and dialect variation, while cloud-based inference costs can make deployment at scale expensive. 

VoxNexus’s solutions run entirely on device, and every query is free once the model is installed on the device. Its speech recognition model has as few as 65 million parameters and achieves a lower word error rate than open-source models nearly ten times its size.

“Under-resource languages aren’t small languages. Hundreds of millions of people speak them. Until now, AI models just haven’t learned them yet,” said Charles Shi, CEO of VoxNexus.

VoxNexus also launched VoxSense, an on-device ambient listening solution that uses only 162 mAh for 12 hours of continuous listening, around 2.5% of a 6,500 mAh phone battery. By keeping all processing on device, VoxSense makes always-on listening practical without draining the battery and without sending any audio to the cloud. Developers and device makers can easily integrate it through a license and a simple SDK. Developers can request a free trial here: www.VoxNexus.ai.

VoxSense and VoxEdge were unveiled at the MediaTek Dimensity 9600 launch in Madrid on October 19.

Distributed by APO Group on behalf of VoxNexus AI. 

About VoxNexus:
VoxNexus builds AI that hears and speaks — for everyone, everywhere, all the time. Its audio intelligence runs entirely on-device, delivering low latency, built-in privacy, and zero token cost across any device with a chip. VoxNexus is headquartered in Singapore. Website: www.VoxNexus.ai. Contact: public@voxnexus.ai  

VoxNexus demonstrates live on-device speech recognition at the MediaTek Dimensity 9600 launch in Madrid on Oct. 19, 2026. Spanish and English conversations were transcribed in real time on the phone, with no cloud connection. (Photo: VoxNexus) 

Speaks Your Language, No Internet Needed: VoxNexus Brings On-Device Voice Artificial Intelligence (AI) in 100+ Languages to Affordable Android Devices

View original content:https://www.prnewswire.com/news-releases/hears-everything-uploads-nothing-voxnexus-launches-androids-first-low-power-on-device-always-on-voice-artificial-intelligence-ai-302918304.html

SOURCE VoxNexus AI

Continue Reading

Technology

team.blue extends €1.1 billion of its Term Loan B to 2032 in the largest software Euro term loan issuance in the last 12 months

Published

on

By

GHENT, Belgium, Oct. 23, 2026 /PRNewswire/ — team.blue, a leading pan-European provider of digital solutions for small and medium-sized businesses (SMBs) backed by Hg, CPP Investments and Sofina, today announces the successful pricing of an amendment and maturity extension for €1.1 billion of its existing €1.35 billion Term Loan B. The transaction priced on 22 October 2026, with the refinanced tranche extended from September 2029 to July 2032, reinforcing the Company’s prudent capital structure approach.

Strong demand from a broad group of institutional investors enabled team.blue to upsize the transaction twice in-market, taking the final deal size to €1.1 billion from a minimum initial launch size of €500 million, despite recent credit market volatility. Pro forma for the transaction, c.90% of team.blue’s term debt now matures in 2032.

The transaction comes at a time of significant momentum for team.blue, with continued double-digit revenue growth and strong cash generation supporting its deleveraging trajectory. Its products help Europe’s SMBs get online, get customers, get paid and stay compliant, and AI-enabled products are increasingly driving new customer growth. team.blue continues to innovate across its portfolio, from smarter tools within its brands to secure European cloud hosting built for customers’ growing AI workloads. Its category-leading SaaS brands are also integrating with leading AI assistants, bringing team.blue’s products to customers wherever they work.

Transaction highlights

The largest software Euro term loan issuance in the last 12 months€1.1 billion Term Loan B, borrowed by team.blue Finco S.à r.l., maturing July 2032Priced at E + 425bps with a 0% floor and an OID of 98.5Upsized twice from an initial €500 million, reflecting a heavily oversubscribed order bookCorporate and facility ratings of B3 (Moody’s) and B (S&P), both with stable outlooksBofA acted as Global Coordinator and Left Lead Physical Bookrunner, alongside Barclays. ABN AMRO, BNP Paribas, Citi, ING and J.P. Morgan acted as Bookrunners

Jonathan Thackray, Chief Financial Officer of team.blue, said:
“We set out to extend €500 million of our Term Loan B, and the depth of support from our institutional investor base allowed us to go much further. This reflects confidence in team.blue’s highly recurring, cash-generative model and our position as a leading digital partner for Europe’s SMBs. It gives us the flexibility to keep innovating and investing in the digital and AI-enabled tools our customers rely on.”

About team.blue
team.blue is the pan-European digital partner for small and medium businesses, serving more than 3.5 million customers in 24 countries. From web hosting, domains, email and cloud and AI infrastructure to e-commerce, engagement, payments and compliance tools, team.blue helps SMBs get online, get customers, get paid and stay compliant. Supported by more than 4,000 employees, team.blue’s vision is to make online business success simpler, with artificial intelligence at every step. 

View original content:https://www.prnewswire.co.uk/news-releases/teamblue-extends-1-1-billion-of-its-term-loan-b-to-2032-in-the-largest-software-euro-term-loan-issuance-in-the-last-12-months-302918306.html

Continue Reading

Trending